News and Publications

News Releases and Articles

Novel Gene Therapy for Bladder Cancer Shows Strong Results in Animal Studies - Gene therapy that causes the bladder to act like a “bioreactor” to produce and secrete the anti-cancer agent interferon-alpha has shown dramatic benefits in preclinical tests, say researchers at The University of Texas MD Anderson Cancer Center. (MD Anderson News Release, 09/07/04)

SPORE Grants Fuel Genitourinary Cancer Program [need link]- Two prestigious grants for bladder and prostate cancers let MD Anderson researchers build upon important advances they've already made. (Conquest, Fall 2001)

MD Anderson Receives SPORE Grant for Bladder Cancer Research - Institution is first to hold two special federal grants for genitourinary cancers. (MD Anderson News Release, 10/22/01)

Publications

2008

Inamoto T, Papineni S, Chintharlapalli S, Cho SD, Safe S, Kamat AM. 1,1-Bis(3'-indolyl)-1-(p-chlorophenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growth. Mol Cancer Ther. 7(12):3825-33, 2008.

Yang H, Dinney CP, Ye Y, Zhu Y, Grossman HB, and Wu X. Evaluation of Genetic Variants in MicroRNA-related Genes and Risk of Bladder Cancer. Cancer Res. 68(7): 2530-2537, 2008

Pirollo KF, Rait A, Zhou Q, Zhang X-Q, Zhou J, Chang-Soo K, Benedict WF and Chang EH. Tumor-Targeting Nanocomplex Delivery of Novel Tumor Suppressor RB94 Chemosensitizes Bladder Carcinoma Cells in vitro and in vivo. Clin Cancer Res. (14)7: 2190 - 2198, 2008

2007

Lee S, Jeong J, Majewski T, Scherer S, Kim MS, Tuziak T, Tang KS, Baggerly K, Grossman HB, Zhou JH, Shen L, Bondaruk J, Ahmed SS, Samanta S, Spiess PE, Wu X, Filipek S, McConkey D, Bar-Eli M, Issa JP, Benedict WF, and Czerniak B. Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia. PNAS. 104(34): 13732-13737, 2007

Zhang X, Yang Z, Dong L, Papageorgiou A, McConkey DJ, and Benedict WF. Adenoviral-mediated interferon alpha overcomes resistance to the interferon protein in various cancer types and has marked bystander effects. Cancer Gene Ther. 14(3): 241-250, 2007

Adam L, Black PC, Kassouf W, Eve B, McConkey D, Munsell MF, Benedict WF, and Dinney CP. Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer. J Urol. 177(5): 1900-1906, 2007

Lee S, Jeong J, Majewski T, Scherer SE, Kim. MS, Tuziak Tang KS, Baggerly K, Grossman HB , Zhou JH, Shen L, Bondaruk J , Ahmed SS, Samanta S, Spiess P Wu X, Filipek S, McConkey D, Bar-Eli M, Issa JP, Benedict WF, and Czerniak B. Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia. Proc Natl Acad Sci. 104(34): 13732-13737, 2007

Nagabhushan TL, Maneval DC, Benedict WF, Wen SF, Ihnat PM, Engler H, and Connor RJ. Enhancement of intravesical delivery with Syn3 potentiates interferon-Ą2b gene therapy for superficial bladder cancer. Cytokine Growth Factor Review. 18: 389-394, 2007

Black PC, Brown GA, and Dinney CP. Clinical and therapeutic significance of aberrant differentiation patterns in bladder cancer. Expert Review of Anticancer Therapy. 7(7):1015-1026, 2007

Adam L, Black PC, Kassouf W, Eve B, McConkey D, Munsell MF, Benedict WF, and Dinney CP. Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer. J Urol. 177(5): 1900-1906, 2007

Zhu Y, Lai M, Yang H, Lin J, Huang M, Grossman HB, Dinney CP, and Wu X. Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer. Carcinogenesis. 28: 698-703, 2007

Wu X, Lin X, Dinney CP, Gu J, and Grossman HB. Genetic polymorphism in bladder cancer. Frontiers in Bioscience. 12: 192-213, 2007

Shrader M, Pino MS, Lashinger L, Bar-Eli M, Adam L, Dinney CP, and McConkey DJ. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res. 67: 1430-1435, 2007

Shrader M, Pino MS, Brown G, Black P, Adam L, Bar-Eli M, Dinney CP, and McConkey DJ. Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Molecular Cancer Therapeutics. 6: 277-285, 2007

Kassouf W, Spiess PE, Brown GA, Munsell MF, Grossman HB, Siefker-Radtke A, Dinney CP, and Kamat AM. P0 Stage at Radical Cystectomy for Bladder Cancer Is Associated with Improved Outcome Independent of Traditional Clinical Risk Factors. European Urology. 2007

Kader AK, Liu J, Shao L, Dinney CP, Lin J, Wang Y, Gu J, Grossman HB, and Wu X. Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness.Clin Cancer Res. 13: 2614-2620, 2007

Zhao H, Lin J, Grossman HB, Hernandez LM, Dinney CP and Wu X. Dietary isothiocyanates, GSTM1, GSTT1, NAT2 polymorphisms and bladder cancer risk. International Journal of Cancer. 120: 2208-2213, 2007

Huang M, Dinney CP, Lin X, Lin J, Grossman HB and Wu X. High-order interactions among genetic variants in DNA base excision repair pathway genes and smoking in bladder cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 16(1):84-91, Jan 2007

Spiess PE, Kassouf W, Steinberg JR, Tuziak T, Hernandez M, Tibbs RF, Czerniak B, Kamat AM, Dinney CP, and Grossman HB. Review of the MD Anderson experience in the treatment of bladder sarcoma. Urologic Oncology. 25(1):38-45, Jan- Feb 2007

2006

Sabichi A, Keyhani A, Tanaka N, Delacerda J, Lee IL, Zou C, Zhou JH, Benedict WF, and Grossman HB. Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression. J Urol. 175(3 Pt 1): 1133-1137, 2006

Kim MS, Jeong J, Majewski T, Kram A, Yoon DS, Zhang RD, Li JZ, Ptaszynski K, Kuang TC, Zhou JH, Sathyanarayana UG, Tuziak T, Johnston DA, Grossman HB, Gazdar AF, Scherer SE, Benedict WF, and Czerniak B. Evidence for alternative candidate genes near RB1 involved in clonal expansionof in situ urothelial neoplasia. Lab Invest. 86(2): 175-190, 2006

Tao Z, Connor RJ, Ashoori F, Dinney CP, Munsell M, Philopena JA, and Benedict WF. Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation. Cancer Gene Ther. 13(2): 125-130. 2006

Mol Cancer Ther. 5: 3032-3041, 2006
Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Papageorgiou A, Kamat A, Benedict WF, Dinney C, and McConkey DJ.

Expert Rev Anticancer Ther. 6/12: 1715-1721, 2006
Urachal carcinoma:surgical and chemotherapeutic options. Siefker-Radtke AO.

Journal of Clinical Oncology. 24: 5528-5535, 2006
Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. Black PC BG, and Dinney CP.

BJU Int. 98(6): 1176-1180, Dec 2006
Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? Brown GA, Busby JE, Wood CG, Pisters LL, Dinney CP, Swanson DA, Grossman HB, Pettaway CA, Munsell MF, Kamat AM, and Matin SF.

Cancer Res. 66(24): 11644-11648, Dec 15, 2006
Matrix metalloproteinase polymorphisms and bladder cancer risk. Kader AK, Shao L, Dinney CP, Schabath MB, Wang Y, Liu J, Gu J, Grossman HB, and Wu X.

Molecular Cancer Ther. 5(12): 3032-3041, Dec 2006
Combination therapy with IFN-{alpha} plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Papageorgiou A, Kamat A, Benedict WF, Dinney C, and McConkey DJ.

Urology. 67(3): 466-471, Mar 2006
Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach? Spiess PE, Kassouf W, Brown G, Highshaw R, Wang X, Do KA, Kamat AM, Czerniak B, Dinney CP, and Grossman HB.

Carcinogenesis. 2006
Genotypes, haplotypes, and diplotypes of XPC and risk of bladder cancer. Zhu Y, Lai M, Yang H, Lin J, Huang M, Grossman HB, Dinney CP, and Wu X.

Am J Hum Genet. 78: 464-479, 2006
Bladder Cancer Predisposition: A Multigenic Approach to DNA-Repair and Cell-Cycle-Control Genes. Wu X, Gu J, Grossman HB, Amos CI, Etzel C, Huang M, Zhang Q, Millikan RE, Lerner S, Dinney CP, and Spitz, MR.

Cancer Gene Ther. 13: 125-130, 2006
Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation. Tao Z, Connor RJ, Ashoori F, Dinney CP, Munsell M, Philopena JA, and Benedict WF.

Cancer Epidemiol Biomarkers Prev. 15: 1746-9, 2006
Personal permanent hair dye use is not associated with bladder cancer risk: evidence from a case-control study. Lin J, Dinney CP, Grossman HB, and Wu X.

J Urol. 176: 787-92, 2006
Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. Kassouf W, Luongo T, Brown G, Adam L, and Dinney CP.

J Urol. 176: 53-7; discussion 57, 2006
Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy. Kassouf W, Leibovici D, Munsell MF, Dinney CP, Grossman HB, and Kamat AM.

Cancer. 107: 1491-1495, 2006
Relevance of extracapsular extension of pelvic lymph node metastasis in patients with bladder cancer treated in the contemporary era. Kassouf W, Leibovici D, Luongo T, Munsell MF, Vakar F, Dinney CP, Grossman HB, and Kamat AM.

J Urol. 176: 1642-16477, 2006
Vitamins C and k3 sensitize human urothelial tumors to gemcitabine. Kassouf W, Highshaw R, Nelkin GM, Dinney CP, and Kamat AM

J Urol. 175: 881-815, 2006
The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. Kamat AM, Gee JR, Dinney CP, Grossman HB, Swanson DA, Millikan RE, Detry MA, Robinson TL, and Pisters LL.

Nat Clin Pract Urol. 3: 472-473, 2006
A combination of intravesical and BCG electromotive mitomycin for high-risk superficial bladder cancer. Kamat AM, and Dinney CP.

Curr Opin Urol. 16(5): 344-3449, Sep 2006
Should cystectomy only be performed at high-volume hospitals by high-volume surgeons? Black PC, Brown GA, and Dinney CP. 
 
Clin Cancer Res. 12(15): 4671-4677, Aug 1, 2006
Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Blehm KN, Spiess PE, Bondaruk JE, Dujka ME, Villares GJ, Zhao YJ, Bogler O, Aldape KD, Grossman HB, Adam L, McConkey DJ, Czerniak BA, Dinney CP, and Bar-Eli M.

J Clin Oncol. Aug 10; 24(23): 3789-3798. Epub Jun 19, 2006 
Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, Liu J, Etzel CJ, Amos CI, Huang M, Chiang SS, Milas L, Hittelman WN, and Ajani JA.

Cancer. 14; 107(4): 705-711, Jul 2006 
Bladder cancer risk as modified by family history and smoking. Lin J, Spitz MR, Dinney CP, Etzel CJ, Grossman HB, and Wu X.  

Clin Genet.  70(3): 240-245, Sep 2006 
E-cadherin promoter polymorphism (C-160A) and risk of recurrence in patients with superficial bladder cancer. Lin J, Dinney CP, Grossman HB, Jhamb M, Zhu Y, Spitz MR, and Wu X.

J Urol.  175(6): 2058-2062, 2006
Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the MD Anderson Cancer Center experience. Kassouf W, Swanson D, Kamat AM, Leibovici D, Siefker-Radtke A, Munsell MF, Grossman HB, and Dinney CP.

Urology.  67(3): 518-523, 2006
Upper urinary tract tumors with nontransitional histology: a single-center experience. Busby JE, Brown GA, Tamboli P, Kamat AM, Dinney CP, Grossman HB, and Matin SF.

J Urol. 175(3 Pt 1): 1133-1137, 2006
Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression. Sabichi A, Keyhani A, Tanaka N, Delacerda J, Lee IL, Zou C, Zhou JH, Benedict WF, and Grossman HB.

2005

Urology. 66: 769-774, 2005
Glutathione peroxidase 1 gene polymorphism and risk of recurrence in patients with superficial bladder cancer. Zhao H, Liang D, Grossman HB, and Wu X.

Cancer . 104: 30-35, 2005
Increased plasma levels of angiogenin and the risk of bladder carcinoma: from initiation ot recurrence. Zhao H, Grossman HB, Delclos GL, Hwang LY, Troisi CL, Chamberlain RM, Chenoweth MA, Zhang H, Spitz MR, and Wu X.

Neoplasia. 7: 912-920, 2005
The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. Mohamedali KA, Kedar D, Sweeney P, Kamat A, Davis DW, Eve BY, Huang S, Thorpe PE, Dinney CP, and Rosenblum MG.

Cancer Res.  65(22): 10524-10535, 2005
Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Kassouf W, Dinney CP, Brown G, McConkey DJ, Diehl AJ, Bar-Eli M, and Adam L.

Urologic Clinics of North America.  32: 239-246, 2005
Clinical applications for targeted therapy in bladder cancer. Adam L, Kassouf W, and Dinney CP. 

Clin Cancer Res. 11: 678-689, 2005
Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, Stadler WM, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, and McConkey DJ.

Clin Cancer Res. 11: 1408-1415, 2005
Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. Gu J, Zhao H, Dinney CP, Zhu Y, Leibovici D, Bermejo CE, Grossman HB, and Wu X.

Laboratory Investigation. 85: 532-549, 2005
Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways. Kim JH, Tuziak T, Hu L, Wang Z, Bondaruk J, Kim M, Fuller G, Dinney C, Grossman HB, Baggerly K, Zhang W, and Czerniak B.  

Cancer Res.  65: 4902-4908, 2005
Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Lashinger, LM, Zhu K, Williams SA, Shrader M, Dinney CP, and McConkey DJ. 

Journal of Clinical Oncology. 23: 5746-5756, 2005
Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. Leibovici D, Grossman HB, Dinney CP, Millikan RE, Lerner S , Wang Y, Gu J, Dong Q, and Wu X.  

Cancer Epidemiol Biomarkers Prev. 14: 878-884, 2005
Polymorphisms in XPD exons 10 and 23 and bladder cancer risk. Schabath MB, Delclos GL, Grossman HB, Wang Y, Lerner SP, Chamberlain RM, Spitz MR, and Wu X.

2004

Molecular Therapy. 9: 305-310, 2004
Model of unidirectional transluminal gene transfer.
Arap MA, Lahdenranta J, Hajitou A, Marini FC III, Wood CG, Wright KC, Fueyo J, Arap W, and Pasqualini R.

Molecular Therapy. 10:525-532, 2004
Intravesical Ad-IFNa causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFNa protein.
Benedict WF, Tao Z, Kim C-S, Zhang X, Zhou JH, Adam L, McConkey DJ, Papageorgiou A, Munsell M, Philopena J, Engler H, Demers W, Maneval DC, Dinney CPN, and Connor RJ.

Cancer Res.  64(13): 4601-4610, 2004
Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. Davis DW, Inoue K, Dinney CP, Hicklin DJ, Abbruzzese JL, and McConkey DJ.

Clin Cancer Res. 10(1 Pt 1): 33-42, 2004
Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Davis DW, Shen Y, Mullani NA, Wen S, Herbst RS, O'Reilly M, Abbruzzese JL, and McConkey DJ.

Cancer Cell. 6(2):111-116, 2004
Focus on bladder cancer (editorial). Dinney CPN, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Kamat A, Siefker-Radtke AO, Adam L, Tuziak T, Sabichi AL, Grossman HB, Benedict WF, and Czerniak B.

Genes Chromosomes Cancer. 41(4): 330-338, 2004
Benzo[a]pyrene diol epoxide-induced 9p21 aberrations associated with genetic predisposition to bladder cancer. Hazra A, Grossman HB, Zhu Y, Luo S, Spitz MR, and Wu X.

Current Opinion in Urology. 14(5): 295-300, 2004
Integrating basic science and clinical research in bladder cancer: update from the first bladder Specialized Program of Research Excellence (SPORE).
Highshaw RA, McConkey DJ, and Dinney CP.

Carcinogenesis. 25(9):1639-1647, 2004
Polymorphisms of folate metabolic genes and susceptibility to bladder cancer: a case-control study. Lin J, Spitz MR, Wang Y, Schabath, MB, Gorlov IP, Hernandez LM, Pillow PC, Grossman HB, and Wu X.

Cancer Res. 64(24): 8973-8979, 2004
Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells. Papageorgiou A, Lashinger L, Millikan R, Grossman HB, Benedict W, Dinney CP, and McConkey DJ.

Journal of Nutrition. 134(12):3362-3369, 2004
Dietary carotenoids and genetic instability modify bladder cancer risk.  Schabath MB, Grossman HB, Delclos GL, Hernandez LM, Day RS, Davis BR, Lerner SP, Spitz MR, and Wu X.

Genes Chromosomes Cancer. 41(4): 379-389, 2004
Specific chromosome aberrations in peripheral blood lymphocytes are associated with risk of bladder cancer. Shao L, Lerner SL, Bondaruk J, Czerniak BA, Zeng X, Grossman HB, Spitz MR, and Wu X.

Oncogene. 23: 6500-6523, 2004
Genetic susceptibility to tobacco-related cancer. Wu X, Zhao H, Suk R, and Christiani DC.

Cancer Res. 64: 2251-2257, 2004
An evolutionary perspective on single-nucleotide polymorphism screening in molecular cancer epidemiology. Zhu Y, Spitz MR, Amos CI, Lin J, Schabath MB, and Wu X.

Cancer. 100: 1853-1858, 2004
Methyl-CpG-binding domain 2: a protective role in bladder cancer. Zhu Y, Spitz MR, Zhang H, Grossman HB, Frazier ML, and Wu X.

J Urol. 172(2): 481-484, Aug 2004
Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the MD Anderson cancer experience.
Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C, Shen Y, Pisters LL, Grossman HB, Swanson DA, and Millikan RE.

Molecular Cancer Therapeutics. 3(3): 279-290, Mar 2004
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, Shen Y, Dinney CP, and McConkey DJ.

Cancer Res. 64: 2251-2257, 2004
An evolutionary perspective on single-nucleotide polymorphism screening in molecular cancer epidemiology. Zhu Y, Spitz MR, Amos CI, Lin J, Schabath MB, and Wu X.

J Urol. 171(2 Pt 1): 570-574, Feb 2004
Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. Slaton JW, Millikan R, Inoue K, Karashima T, Czerniak B, Shen Y, Yang Y, Benedict WF, and Dinney CP.

J Urol. 171(1): 145-148, Jan 2004
Is there a role for surgery in the management of metastatic urothelial cancer? The MD Anderson experience. Siefker-Radtke AO, Walsh GL, Pisters LL, Shen Y, Swanson DA, Logothetis CJ, and Millikan RE.

2003

J Urol. 170(3): 975-978, Sep 2003
Noninvasive detection of bladder cancer in an orthotopic murine model with green fluorescence protein cytology. Tanaka M, Gee JR, De La Cerda J, Rosser CJ, Zhou JH, Benedict WF, and Grossman HB.

Clin Cancer Res. 9(8): 3167-3175, Aug 2003
Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Mian BM, Dinney CP, Bermejo CE, Sweeney P, Tellez C, Yang XD, Gudas JM, McConkey DJ, and Bar-Eli M.

Journal of the National Cancer Institute. 95(16): 1211-1218, 2003
Telomere Dysfunction: A Cancer Predisposition Factor? Wu X, Amos CI, Zhu Y, Zhao H, Grossman BH, Shay JW, Luo S, Hong WK, and Spitz MR.

Clin Cancer Res. 9(7): 2786-2797, Jul 2003
Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Karashima T, Sweeney P, Kamat A, Huang S, Kim SJ, Bar-Eli M, McConkey DJ, and Dinney CP.

J Urol. 169(6): 2113-2117, June 2003
Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? Sweeney P, Millikan R, Donat M, Wood CG, Radtke AS, Pettaway CA, Grossman HB, Dinney CPN, Swanson DA, and Pisters LL.

Journal of Clinical Oncology. 15:2247-2253, Jun 2003
Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: A phase I study of p53 gene therapy. Pagliaro LC, Keyhani A, Williams D, Woods D, Liu B, Perrotte P, Slaton JW, Merritt JA, Grossman HP, and Dinney CP.

Mutation Research. Genetic Toxicology and Environmental Mutagenesis. 20; 536(1-2):131-137, Apr 2003
An association between NQO1 genetic polymorphism and risk of bladder cancer. Park SJ, Zhao H, Spitz MR, Grossman HB, and Wu X.

J Urol. 169(4): 1535-1540, Apr 2003
Targeting urothelium: Ex vivo assay standardization and selection of internalizing ligands. Ardelt PU, Wood CG, Chen L, Mintz PJ, Moya C, Arap MA, Wright KC, Pasqualini R, and Arap W.

J Urol. 169(4):1295-1298, Apr 2003
Multimodality management of urachal carcinoma: the MD Anderson Cancer Center experience. Siefker-Radtke AO, Gee J, Shen Y, Wen S, Daliani D, Millikan RE, and Pisters LL.

J Natl Cancer Inst. 95: 540-547, Apr 2003
Genetic instability in bladder cancer assessed by the comet assay. Schabath MB, Spitz MR, Grossman HB, Zhang K, Dinney CP, Zheng PJ, and Wu X.

Cancer Res. 63: 1157-1159, Mar 2003
Death receptor 4 and bladder cancer risk.
Hazra A, Chamberlain RM, Grossman HB, Zhu Y, Spitz MR, and Wu X.

J Urol. 169(2): 714-717, Feb 2003
Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. Zhao H, Grossman HB, Spitz MR, Lerner SP, Zhang K, and Wu X.

Cancer Res. 63: 760-765, Feb 2003
Adenoviral-mediated retinoblastoma 94 produces rapid telomere erosion, chromosomal crisis, and caspase-dependent apoptosis in bladder cancer and immortalized human urothelial cells, but not in normal urothelial cells. Zhang X, Multani AS, Zhou JH, Shay JW, McConkey D, Dong L, Kim CS, Rosser CJ, Pathak S, and Benedict WF.

Cancer Letters. 8;202(1): 61-69, Dec 2003
Sulfotransferase 1A1 (SULT1A1) polymorphism and bladder cancer risk: a case-control study. Zheng L, Wang Y, Schabath MB, Grossman HB, and Wu X.

2002

Cancer Gene Ther. 9(8): 687-91, Aug 2002
Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. Yamashita M, Rosser CJ, Zhou JH, Zhang XQ, Connor RJ, Engler H, Maneval DC, Karashima T, Czerniak BA, Dinney CP, and Benedict WF.

Cancer Gene Ther. 9(8): 681-686, Aug 2002
Visualizing superficial human bladder cancer cell growth in vivo by green fluorescent protein expression. Zhou JH, Rosser CJ, Tanaka M, Yang M, Baranov E, Hoffman RM, and Benedict WF.

Clin Cancer Res. 8(4): 1258-1270, Apr 2002
Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Izawa JI, Sweeney P, Perrotte P, Kedar D, Dong Z, Slaton JW, Karashima T, Inoue K, Benedict WF, and Dinney CP.

2001

Cancer Epidemiol Biomarkers Prev. 10: 391-395, 2001
Effects of novel phenylretinamides on cell growth and apoptosis in bladder cancer. Clifford JL, Sabichi AL, Zou C, Yang X, Steele VE, Kelloff GJ, Lotan R, and Lippman SM.

Clin Cancer Res. 7: 2840-2853, 2001
Treatment with Low-Dose Interferon-alpha Restores the Balance between Matrix Metalloproteinase-9 and E-Cadherin Expression in Human Transitional Cell Carcinoma of the Bladder. Slaton JW, Karashima T, Perrotte P, Inoue K, Kim SJ, Izawa J, Kedar D, McConkey DJ, Millikan R, Sweeney P, Yoshikawa C, Shuin T, and Dinney CP.

Gene Ther. 8: 139-148, 2001
Connexin 26 enhances the bystander effect in HSVtk/GCV gene therapy for human bladder cancer by adenovirus/PLL/DNA gene delivery. Tanaka M, Fraizer GC, De La Cerda J, Cristiano RJ, Liebert M, and Grossman HB.

Journal of Clinical Oncology. 19: 4005-4013, 2001
Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. Millikan R, Dinney C, Swanson D, Sweeney P, Ro JY, Smith TL, Williams D and Logothetis C.

Lab Invest. 81: 1039-1048, 2001
Mapping and genome sequence analysis of chromosome 5 regions involved in bladder cancer progression. Kram A, Li L, Zhang RD, Yoon DS, Ro JY, Johnston D, Grossman HB, Scherer S, and Czerniak B.

Oncogene. 20(36): 5005-5014, Aug 16, 2001
Genetic mapping and DNA sequence-based analysis of deleted regions on chromosome 16 involved in progression of bladder cancer from occult preneoplastic conditions to invasive disease. Yoon DS, Li L, Zhang RD, Kram A, Ro JY, Johnston D, Grossman HB, Scherer S, and Czerniak B.

Oncology Rep. 8: 9-15, 2001
Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Izawa JI, Slaton JW, Kedar D, Karashima T, Perrotte P, Czerniak B, Grossman HB, and Dinney CP.

Oncology Rep. 8: 723-726, 2001
Radical cystectomy for invasive bladder cancer in the octogenarian. Lance, RS, Dinney CPN, Swanson D, Babaian RJ, Pisters LL, Palmer JL, and Grossman HB.

2000

Cancer Gene Ther.  7: 1575-1580, 2000
An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies. Watanabe T, Shinohara N, Sazawa A, Harabayashi T, Ogiso Y, Koyanagi T, Takiguchi M, Hashimoto A, Kuzumaki N, Yamashita M, Tanaka M, Grossman HB, and Benedict WF.

Cancer Res. 6: 4422-4431, 2000
Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor. Inoue K, Perrotte P, Wood CG, Slaton JW, Sweeney P, and Dinney CP.

Clin Cancer Res. 6: 4866-4873, 2000
The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Inoue K, Slaton JW, Karashima T, Yoshikawa C, Shuin T, Sweeney P, Millikan R, and Dinney CP.

Clin Cancer Res. 6: 4874-4884, 2000
Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, McConkey DJ, Sweeney P, Radinsky R, and Dinney CP.

Clin Cancer Res. 6: 2635-2643, 2000
Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Inoue K, Slaton JW, Davis DW, Hicklin DJ, McConkey DJ, Karashima T, Radinsky R, and Dinney CP.

Oncogene. 19: 5406-5412, 2000
MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Tanaka M, Koul D, Davies MA, Liebert M, Steck PA, and Grossman HB.

Stat Med. 19: 1011-1028, 2000
Evaluating multiple treatment courses in clinical trials. Thall PF, Millikan RE, and Sung HG.

Urology. 56: 155-159, 2000
Biosafety of in vivo adenovirus-p53 intravesical administration in mice. Perrotte P, Wood M, Slaton JW, Wilson DR, Pagliaro L, Price RE, and Dinney CP.